Table 1

Newcastle early arthritis clinic patients stratified by diagnostic outcome at the end of follow-up

ACPA−RA (n=29)ACPA+RA (n=25)Non-RA inflam. (n=59)OA/non-inflam. (n=71)UA (n=3)p Value (inflam. diagnoses*)p Value (all diagnoses†)
Age (years)61 (30 to 88)58 (27 to 81)51 (18 to 91)51 (27 to 86)45 (24 to 68)0.01<0.01
Female, %6964667267nsns
Symptom duration (weeks)12 (4 to >52)16 (4 to >52)9 (2 to >52)18 (3 to >52)24 (6 to 38)nsns
ESR (seconds)23 (1 to 71)21 (4 to 86)15 (1 to 113)8 (1 to 100)21 (20 to 29)ns0.01
CRP (g/L)11 (<5 to 91)10 (<5 to 66)8 (<5 to 189)<5 (<5 to 49)12 (6 to 23)ns0.01
ACPA+, %0100409<0.01<0.01
RF+, %31805733<0.01<0.01
DAS284.8 (2.31 to 7.16)5.00 (1.59 to 7.07)n/an/an/ans
  • Except where indicated, median and range are given.

  • *Kruskal–Wallis ANOVA analysis confined to three groups with confirmed inflammatory diagnoses at inception: ACPA−RA, ACPA+RA and non-RA inflammatory arthritis.

  • †Kruskal–Wallis ANOVA, five groups, including OA/non-inflammatory arthralgia and UA.

  • ACPA, anticitrullinated peptide autoantibody; ANOVA, analysis of variance; CRP, C reactive protein DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; OA, osteoarthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis.